Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: Results of the randomized, double-blind STARC study

Aleardo Maresta, Marco Balducelli, Luca Cantini, Angelo Casari, Raffaello Chioin, Mauro Fabbri, Alessandro Fontanelli, Pier A. Monici Preti, Sergio Repetto, Stefano De Servi, Elisabetta Varani

Research output: Contribution to journalArticle

Abstract

Background: Trapidil is an antiplatelet drug with specific platelet- derived growth factor antagonism and antiproliferative effects in the rat and rabbit models after balloon angioplasty. Methods and Results: The Studio Trapidil versus Aspirin nella Restenosi Coronarica (STARC) is a multicentric, randomized, double-blind trial to assess the effects of trapidil in angiographic restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA). Patients received either trapidil 100 mg TID or aspirin at the same dosage at least 3 days before angioplasty and for 6 months thereafter. Coronary angiograms before PTCA, after PTCA, and at 6-month follow-up were quantitatively analyzed with manual calipers. Of the initial 384 patients recruited, 254 were evaluable for restenosis analysis (128 trapidil, 126 aspirin). Restenosis, defined as a loss of initial percent gain after PTCA of at least 50% (primary end point), occurred in 24.2% of the trapidil group and 39.7% of the aspirin group (P

Original languageEnglish
Pages (from-to)2710-2715
Number of pages6
JournalCirculation
Volume90
Issue number6
Publication statusPublished - Dec 1994

Keywords

  • angioplasty
  • clinical trials
  • growth substances
  • stenosis
  • trapidil

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: Results of the randomized, double-blind STARC study'. Together they form a unique fingerprint.

  • Cite this

    Maresta, A., Balducelli, M., Cantini, L., Casari, A., Chioin, R., Fabbri, M., Fontanelli, A., Monici Preti, P. A., Repetto, S., De Servi, S., & Varani, E. (1994). Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: Results of the randomized, double-blind STARC study. Circulation, 90(6), 2710-2715.